nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiodarone—CYP1A1—liver cancer	0.358	1	CbGaD
Amiodarone—CYP3A7—Sorafenib—liver cancer	0.0476	0.14	CbGbCtD
Amiodarone—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0476	0.14	CbGbCtD
Amiodarone—CYP3A5—Sorafenib—liver cancer	0.0357	0.105	CbGbCtD
Amiodarone—CYP2C8—Sorafenib—liver cancer	0.0343	0.101	CbGbCtD
Amiodarone—CYP2C19—Sorafenib—liver cancer	0.0288	0.0848	CbGbCtD
Amiodarone—CYP1A2—Sorafenib—liver cancer	0.0266	0.0783	CbGbCtD
Amiodarone—CYP2C9—Sorafenib—liver cancer	0.024	0.0705	CbGbCtD
Amiodarone—ABCB1—Sorafenib—liver cancer	0.0232	0.0685	CbGbCtD
Amiodarone—CYP2D6—Sorafenib—liver cancer	0.0219	0.0645	CbGbCtD
Amiodarone—ABCB1—Doxorubicin—liver cancer	0.0141	0.0415	CbGbCtD
Amiodarone—CYP3A4—Sorafenib—liver cancer	0.0139	0.041	CbGbCtD
Amiodarone—CYP2D6—Doxorubicin—liver cancer	0.0133	0.0391	CbGbCtD
Amiodarone—CYP3A4—Doxorubicin—liver cancer	0.00845	0.0249	CbGbCtD
Amiodarone—Liver injury—Doxorubicin—liver cancer	0.000474	0.00292	CcSEcCtD
Amiodarone—Neoplasm malignant—Doxorubicin—liver cancer	0.000467	0.00287	CcSEcCtD
Amiodarone—Angioedema—Sorafenib—liver cancer	0.000466	0.00287	CcSEcCtD
Amiodarone—Delirium—Doxorubicin—liver cancer	0.000464	0.00285	CcSEcCtD
Amiodarone—Dyskinesia—Epirubicin—liver cancer	0.000459	0.00282	CcSEcCtD
Amiodarone—Extravasation—Doxorubicin—liver cancer	0.000457	0.00281	CcSEcCtD
Amiodarone—Cough—Sorafenib—liver cancer	0.000445	0.00274	CcSEcCtD
Amiodarone—Atrioventricular block—Epirubicin—liver cancer	0.000444	0.00274	CcSEcCtD
Amiodarone—Inflammation—Epirubicin—liver cancer	0.000444	0.00274	CcSEcCtD
Amiodarone—Gait disturbance—Epirubicin—liver cancer	0.000442	0.00272	CcSEcCtD
Amiodarone—Skin discolouration—Doxorubicin—liver cancer	0.000442	0.00272	CcSEcCtD
Amiodarone—Coordination abnormal—Epirubicin—liver cancer	0.000439	0.0027	CcSEcCtD
Amiodarone—Cellulitis—Doxorubicin—liver cancer	0.000439	0.0027	CcSEcCtD
Amiodarone—Hepatocellular injury—Epirubicin—liver cancer	0.000431	0.00265	CcSEcCtD
Amiodarone—Ventricular tachycardia—Epirubicin—liver cancer	0.000431	0.00265	CcSEcCtD
Amiodarone—Injection site reaction—Epirubicin—liver cancer	0.000429	0.00264	CcSEcCtD
Amiodarone—Abnormal dreams—Epirubicin—liver cancer	0.000426	0.00262	CcSEcCtD
Amiodarone—Dry mouth—Sorafenib—liver cancer	0.000425	0.00261	CcSEcCtD
Amiodarone—Dyskinesia—Doxorubicin—liver cancer	0.000424	0.00261	CcSEcCtD
Amiodarone—Salivary hypersecretion—Epirubicin—liver cancer	0.000419	0.00258	CcSEcCtD
Amiodarone—Anaphylactic shock—Sorafenib—liver cancer	0.000416	0.00256	CcSEcCtD
Amiodarone—Infection—Sorafenib—liver cancer	0.000413	0.00254	CcSEcCtD
Amiodarone—Skin exfoliation—Epirubicin—liver cancer	0.000412	0.00253	CcSEcCtD
Amiodarone—Atrioventricular block—Doxorubicin—liver cancer	0.000411	0.00253	CcSEcCtD
Amiodarone—Inflammation—Doxorubicin—liver cancer	0.000411	0.00253	CcSEcCtD
Amiodarone—Shock—Sorafenib—liver cancer	0.000409	0.00252	CcSEcCtD
Amiodarone—Gait disturbance—Doxorubicin—liver cancer	0.000409	0.00252	CcSEcCtD
Amiodarone—Thrombocytopenia—Sorafenib—liver cancer	0.000408	0.00251	CcSEcCtD
Amiodarone—Coordination abnormal—Doxorubicin—liver cancer	0.000406	0.0025	CcSEcCtD
Amiodarone—Neuropathy—Epirubicin—liver cancer	0.000405	0.00249	CcSEcCtD
Amiodarone—Aplastic anaemia—Epirubicin—liver cancer	0.000405	0.00249	CcSEcCtD
Amiodarone—Skin disorder—Sorafenib—liver cancer	0.000404	0.00249	CcSEcCtD
Amiodarone—Hepatocellular injury—Doxorubicin—liver cancer	0.000399	0.00245	CcSEcCtD
Amiodarone—Ventricular tachycardia—Doxorubicin—liver cancer	0.000399	0.00245	CcSEcCtD
Amiodarone—Dry eye—Epirubicin—liver cancer	0.000398	0.00245	CcSEcCtD
Amiodarone—Anorexia—Sorafenib—liver cancer	0.000397	0.00244	CcSEcCtD
Amiodarone—Injection site reaction—Doxorubicin—liver cancer	0.000397	0.00244	CcSEcCtD
Amiodarone—Abnormal dreams—Doxorubicin—liver cancer	0.000394	0.00243	CcSEcCtD
Amiodarone—Ecchymosis—Epirubicin—liver cancer	0.00039	0.0024	CcSEcCtD
Amiodarone—Salivary hypersecretion—Doxorubicin—liver cancer	0.000387	0.00238	CcSEcCtD
Amiodarone—Pulmonary oedema—Epirubicin—liver cancer	0.000384	0.00236	CcSEcCtD
Amiodarone—Skin exfoliation—Doxorubicin—liver cancer	0.000381	0.00234	CcSEcCtD
Amiodarone—Aplastic anaemia—Doxorubicin—liver cancer	0.000375	0.0023	CcSEcCtD
Amiodarone—Neuropathy—Doxorubicin—liver cancer	0.000375	0.0023	CcSEcCtD
Amiodarone—Dyspnoea—Sorafenib—liver cancer	0.000371	0.00228	CcSEcCtD
Amiodarone—Dry eye—Doxorubicin—liver cancer	0.000368	0.00227	CcSEcCtD
Amiodarone—Dyspepsia—Sorafenib—liver cancer	0.000366	0.00225	CcSEcCtD
Amiodarone—Phlebitis—Epirubicin—liver cancer	0.000363	0.00224	CcSEcCtD
Amiodarone—Decreased appetite—Sorafenib—liver cancer	0.000362	0.00223	CcSEcCtD
Amiodarone—Thrombophlebitis—Epirubicin—liver cancer	0.000362	0.00222	CcSEcCtD
Amiodarone—Ecchymosis—Doxorubicin—liver cancer	0.000361	0.00222	CcSEcCtD
Amiodarone—Gastrointestinal disorder—Sorafenib—liver cancer	0.000359	0.00221	CcSEcCtD
Amiodarone—Fatigue—Sorafenib—liver cancer	0.000359	0.00221	CcSEcCtD
Amiodarone—Hepatic function abnormal—Epirubicin—liver cancer	0.000358	0.0022	CcSEcCtD
Amiodarone—Photosensitivity—Epirubicin—liver cancer	0.000356	0.00219	CcSEcCtD
Amiodarone—Pain—Sorafenib—liver cancer	0.000356	0.00219	CcSEcCtD
Amiodarone—Constipation—Sorafenib—liver cancer	0.000356	0.00219	CcSEcCtD
Amiodarone—Pulmonary oedema—Doxorubicin—liver cancer	0.000355	0.00219	CcSEcCtD
Amiodarone—Eczema—Epirubicin—liver cancer	0.000348	0.00214	CcSEcCtD
Amiodarone—Hepatic failure—Epirubicin—liver cancer	0.000348	0.00214	CcSEcCtD
Amiodarone—Cardiac failure congestive—Epirubicin—liver cancer	0.000345	0.00212	CcSEcCtD
Amiodarone—Gastrointestinal pain—Sorafenib—liver cancer	0.00034	0.00209	CcSEcCtD
Amiodarone—Renal failure acute—Epirubicin—liver cancer	0.000339	0.00209	CcSEcCtD
Amiodarone—Phlebitis—Doxorubicin—liver cancer	0.000336	0.00207	CcSEcCtD
Amiodarone—Hot flush—Epirubicin—liver cancer	0.000335	0.00206	CcSEcCtD
Amiodarone—Thrombophlebitis—Doxorubicin—liver cancer	0.000335	0.00206	CcSEcCtD
Amiodarone—Dermatitis exfoliative—Epirubicin—liver cancer	0.000332	0.00204	CcSEcCtD
Amiodarone—Menopausal symptoms—Epirubicin—liver cancer	0.000332	0.00204	CcSEcCtD
Amiodarone—Hepatic function abnormal—Doxorubicin—liver cancer	0.000331	0.00204	CcSEcCtD
Amiodarone—Urticaria—Sorafenib—liver cancer	0.000331	0.00203	CcSEcCtD
Amiodarone—Photosensitivity—Doxorubicin—liver cancer	0.00033	0.00203	CcSEcCtD
Amiodarone—Body temperature increased—Sorafenib—liver cancer	0.000329	0.00202	CcSEcCtD
Amiodarone—Abdominal pain—Sorafenib—liver cancer	0.000329	0.00202	CcSEcCtD
Amiodarone—Renal impairment—Epirubicin—liver cancer	0.000329	0.00202	CcSEcCtD
Amiodarone—Anaphylactoid reaction—Epirubicin—liver cancer	0.000323	0.00199	CcSEcCtD
Amiodarone—Eczema—Doxorubicin—liver cancer	0.000322	0.00198	CcSEcCtD
Amiodarone—Hepatic failure—Doxorubicin—liver cancer	0.000322	0.00198	CcSEcCtD
Amiodarone—Cardiac failure—Epirubicin—liver cancer	0.000321	0.00197	CcSEcCtD
Amiodarone—Cardiac failure congestive—Doxorubicin—liver cancer	0.000319	0.00196	CcSEcCtD
Amiodarone—Renal failure acute—Doxorubicin—liver cancer	0.000314	0.00193	CcSEcCtD
Amiodarone—Hot flush—Doxorubicin—liver cancer	0.00031	0.0019	CcSEcCtD
Amiodarone—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000307	0.00189	CcSEcCtD
Amiodarone—Menopausal symptoms—Doxorubicin—liver cancer	0.000307	0.00189	CcSEcCtD
Amiodarone—Hypersensitivity—Sorafenib—liver cancer	0.000307	0.00189	CcSEcCtD
Amiodarone—Renal impairment—Doxorubicin—liver cancer	0.000304	0.00187	CcSEcCtD
Amiodarone—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000299	0.00184	CcSEcCtD
Amiodarone—Asthenia—Sorafenib—liver cancer	0.000299	0.00184	CcSEcCtD
Amiodarone—Cardiac arrest—Epirubicin—liver cancer	0.000298	0.00183	CcSEcCtD
Amiodarone—Cardiac failure—Doxorubicin—liver cancer	0.000297	0.00183	CcSEcCtD
Amiodarone—Pruritus—Sorafenib—liver cancer	0.000294	0.00181	CcSEcCtD
Amiodarone—Ataxia—Epirubicin—liver cancer	0.000294	0.00181	CcSEcCtD
Amiodarone—Liver function test abnormal—Epirubicin—liver cancer	0.000289	0.00178	CcSEcCtD
Amiodarone—Diarrhoea—Sorafenib—liver cancer	0.000285	0.00175	CcSEcCtD
Amiodarone—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000282	0.00173	CcSEcCtD
Amiodarone—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000282	0.00173	CcSEcCtD
Amiodarone—Muscular weakness—Epirubicin—liver cancer	0.000276	0.0017	CcSEcCtD
Amiodarone—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000276	0.0017	CcSEcCtD
Amiodarone—Cardiac arrest—Doxorubicin—liver cancer	0.000275	0.00169	CcSEcCtD
Amiodarone—Dizziness—Sorafenib—liver cancer	0.000275	0.00169	CcSEcCtD
Amiodarone—Ataxia—Doxorubicin—liver cancer	0.000272	0.00168	CcSEcCtD
Amiodarone—Eosinophilia—Epirubicin—liver cancer	0.000268	0.00165	CcSEcCtD
Amiodarone—Liver function test abnormal—Doxorubicin—liver cancer	0.000267	0.00165	CcSEcCtD
Amiodarone—Pancreatitis—Epirubicin—liver cancer	0.000265	0.00163	CcSEcCtD
Amiodarone—Vomiting—Sorafenib—liver cancer	0.000265	0.00163	CcSEcCtD
Amiodarone—Angina pectoris—Epirubicin—liver cancer	0.000263	0.00162	CcSEcCtD
Amiodarone—Rash—Sorafenib—liver cancer	0.000262	0.00161	CcSEcCtD
Amiodarone—Dermatitis—Sorafenib—liver cancer	0.000262	0.00161	CcSEcCtD
Amiodarone—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000261	0.0016	CcSEcCtD
Amiodarone—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000261	0.0016	CcSEcCtD
Amiodarone—Headache—Sorafenib—liver cancer	0.000261	0.0016	CcSEcCtD
Amiodarone—Pancytopenia—Epirubicin—liver cancer	0.000257	0.00158	CcSEcCtD
Amiodarone—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000255	0.00157	CcSEcCtD
Amiodarone—Muscular weakness—Doxorubicin—liver cancer	0.000255	0.00157	CcSEcCtD
Amiodarone—Neutropenia—Epirubicin—liver cancer	0.000253	0.00156	CcSEcCtD
Amiodarone—Eosinophilia—Doxorubicin—liver cancer	0.000248	0.00152	CcSEcCtD
Amiodarone—Nausea—Sorafenib—liver cancer	0.000247	0.00152	CcSEcCtD
Amiodarone—Photosensitivity reaction—Epirubicin—liver cancer	0.000247	0.00152	CcSEcCtD
Amiodarone—Weight increased—Epirubicin—liver cancer	0.000246	0.00151	CcSEcCtD
Amiodarone—Pancreatitis—Doxorubicin—liver cancer	0.000245	0.00151	CcSEcCtD
Amiodarone—Weight decreased—Epirubicin—liver cancer	0.000245	0.00151	CcSEcCtD
Amiodarone—Angina pectoris—Doxorubicin—liver cancer	0.000244	0.0015	CcSEcCtD
Amiodarone—Pneumonia—Epirubicin—liver cancer	0.000243	0.00149	CcSEcCtD
Amiodarone—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000239	0.00147	CcSEcCtD
Amiodarone—Pancytopenia—Doxorubicin—liver cancer	0.000238	0.00146	CcSEcCtD
Amiodarone—Renal failure—Epirubicin—liver cancer	0.000237	0.00146	CcSEcCtD
Amiodarone—Neuropathy peripheral—Epirubicin—liver cancer	0.000236	0.00145	CcSEcCtD
Amiodarone—Jaundice—Epirubicin—liver cancer	0.000235	0.00145	CcSEcCtD
Amiodarone—Neutropenia—Doxorubicin—liver cancer	0.000234	0.00144	CcSEcCtD
Amiodarone—Sweating—Epirubicin—liver cancer	0.000231	0.00142	CcSEcCtD
Amiodarone—Photosensitivity reaction—Doxorubicin—liver cancer	0.000228	0.00141	CcSEcCtD
Amiodarone—Weight increased—Doxorubicin—liver cancer	0.000228	0.0014	CcSEcCtD
Amiodarone—Weight decreased—Doxorubicin—liver cancer	0.000226	0.00139	CcSEcCtD
Amiodarone—Agranulocytosis—Epirubicin—liver cancer	0.000225	0.00139	CcSEcCtD
Amiodarone—Pneumonia—Doxorubicin—liver cancer	0.000224	0.00138	CcSEcCtD
Amiodarone—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000221	0.00136	CcSEcCtD
Amiodarone—Bradycardia—Epirubicin—liver cancer	0.00022	0.00136	CcSEcCtD
Amiodarone—Renal failure—Doxorubicin—liver cancer	0.000219	0.00135	CcSEcCtD
Amiodarone—Neuropathy peripheral—Doxorubicin—liver cancer	0.000219	0.00135	CcSEcCtD
Amiodarone—Jaundice—Doxorubicin—liver cancer	0.000218	0.00134	CcSEcCtD
Amiodarone—Hepatitis—Epirubicin—liver cancer	0.000216	0.00133	CcSEcCtD
Amiodarone—Sweating—Doxorubicin—liver cancer	0.000214	0.00132	CcSEcCtD
Amiodarone—Visual impairment—Epirubicin—liver cancer	0.000209	0.00128	CcSEcCtD
Amiodarone—Agranulocytosis—Doxorubicin—liver cancer	0.000208	0.00128	CcSEcCtD
Amiodarone—Erythema multiforme—Epirubicin—liver cancer	0.000205	0.00126	CcSEcCtD
Amiodarone—Bradycardia—Doxorubicin—liver cancer	0.000204	0.00125	CcSEcCtD
Amiodarone—Tinnitus—Epirubicin—liver cancer	0.000202	0.00124	CcSEcCtD
Amiodarone—Flushing—Epirubicin—liver cancer	0.000201	0.00124	CcSEcCtD
Amiodarone—Hepatitis—Doxorubicin—liver cancer	0.0002	0.00123	CcSEcCtD
Amiodarone—Arrhythmia—Epirubicin—liver cancer	0.000193	0.00119	CcSEcCtD
Amiodarone—Visual impairment—Doxorubicin—liver cancer	0.000193	0.00119	CcSEcCtD
Amiodarone—Alopecia—Epirubicin—liver cancer	0.000191	0.00118	CcSEcCtD
Amiodarone—Erythema multiforme—Doxorubicin—liver cancer	0.000189	0.00117	CcSEcCtD
Amiodarone—Erythema—Epirubicin—liver cancer	0.000188	0.00116	CcSEcCtD
Amiodarone—Tinnitus—Doxorubicin—liver cancer	0.000187	0.00115	CcSEcCtD
Amiodarone—Flushing—Doxorubicin—liver cancer	0.000186	0.00114	CcSEcCtD
Amiodarone—Dysgeusia—Epirubicin—liver cancer	0.000185	0.00114	CcSEcCtD
Amiodarone—Back pain—Epirubicin—liver cancer	0.000182	0.00112	CcSEcCtD
Amiodarone—Arrhythmia—Doxorubicin—liver cancer	0.000179	0.0011	CcSEcCtD
Amiodarone—Vision blurred—Epirubicin—liver cancer	0.000178	0.00109	CcSEcCtD
Amiodarone—Alopecia—Doxorubicin—liver cancer	0.000177	0.00109	CcSEcCtD
Amiodarone—Ill-defined disorder—Epirubicin—liver cancer	0.000175	0.00108	CcSEcCtD
Amiodarone—Erythema—Doxorubicin—liver cancer	0.000174	0.00107	CcSEcCtD
Amiodarone—Agitation—Epirubicin—liver cancer	0.000173	0.00107	CcSEcCtD
Amiodarone—Dysgeusia—Doxorubicin—liver cancer	0.000171	0.00105	CcSEcCtD
Amiodarone—Malaise—Epirubicin—liver cancer	0.00017	0.00105	CcSEcCtD
Amiodarone—Vertigo—Epirubicin—liver cancer	0.000169	0.00104	CcSEcCtD
Amiodarone—Back pain—Doxorubicin—liver cancer	0.000169	0.00104	CcSEcCtD
Amiodarone—Cough—Epirubicin—liver cancer	0.000164	0.00101	CcSEcCtD
Amiodarone—Vision blurred—Doxorubicin—liver cancer	0.000164	0.00101	CcSEcCtD
Amiodarone—Ill-defined disorder—Doxorubicin—liver cancer	0.000162	0.000996	CcSEcCtD
Amiodarone—Agitation—Doxorubicin—liver cancer	0.00016	0.000986	CcSEcCtD
Amiodarone—Anxiety—Epirubicin—liver cancer	0.00016	0.000984	CcSEcCtD
Amiodarone—Discomfort—Epirubicin—liver cancer	0.000159	0.000976	CcSEcCtD
Amiodarone—Malaise—Doxorubicin—liver cancer	0.000157	0.000968	CcSEcCtD
Amiodarone—Dry mouth—Epirubicin—liver cancer	0.000157	0.000966	CcSEcCtD
Amiodarone—Vertigo—Doxorubicin—liver cancer	0.000157	0.000964	CcSEcCtD
Amiodarone—Confusional state—Epirubicin—liver cancer	0.000155	0.000954	CcSEcCtD
Amiodarone—Oedema—Epirubicin—liver cancer	0.000154	0.000947	CcSEcCtD
Amiodarone—Anaphylactic shock—Epirubicin—liver cancer	0.000154	0.000947	CcSEcCtD
Amiodarone—Infection—Epirubicin—liver cancer	0.000153	0.00094	CcSEcCtD
Amiodarone—Cough—Doxorubicin—liver cancer	0.000152	0.000936	CcSEcCtD
Amiodarone—Shock—Epirubicin—liver cancer	0.000151	0.000931	CcSEcCtD
Amiodarone—Thrombocytopenia—Epirubicin—liver cancer	0.000151	0.000927	CcSEcCtD
Amiodarone—Tachycardia—Epirubicin—liver cancer	0.00015	0.000924	CcSEcCtD
Amiodarone—Skin disorder—Epirubicin—liver cancer	0.000149	0.000919	CcSEcCtD
Amiodarone—Hyperhidrosis—Epirubicin—liver cancer	0.000149	0.000915	CcSEcCtD
Amiodarone—Anxiety—Doxorubicin—liver cancer	0.000148	0.00091	CcSEcCtD
Amiodarone—Discomfort—Doxorubicin—liver cancer	0.000147	0.000903	CcSEcCtD
Amiodarone—Anorexia—Epirubicin—liver cancer	0.000147	0.000902	CcSEcCtD
Amiodarone—Dry mouth—Doxorubicin—liver cancer	0.000145	0.000894	CcSEcCtD
Amiodarone—Hypotension—Epirubicin—liver cancer	0.000144	0.000884	CcSEcCtD
Amiodarone—Confusional state—Doxorubicin—liver cancer	0.000144	0.000883	CcSEcCtD
Amiodarone—Oedema—Doxorubicin—liver cancer	0.000142	0.000876	CcSEcCtD
Amiodarone—Anaphylactic shock—Doxorubicin—liver cancer	0.000142	0.000876	CcSEcCtD
Amiodarone—Infection—Doxorubicin—liver cancer	0.000141	0.00087	CcSEcCtD
Amiodarone—Shock—Doxorubicin—liver cancer	0.00014	0.000862	CcSEcCtD
Amiodarone—Thrombocytopenia—Doxorubicin—liver cancer	0.000139	0.000858	CcSEcCtD
Amiodarone—Insomnia—Epirubicin—liver cancer	0.000139	0.000856	CcSEcCtD
Amiodarone—Tachycardia—Doxorubicin—liver cancer	0.000139	0.000855	CcSEcCtD
Amiodarone—Skin disorder—Doxorubicin—liver cancer	0.000138	0.000851	CcSEcCtD
Amiodarone—Paraesthesia—Epirubicin—liver cancer	0.000138	0.00085	CcSEcCtD
Amiodarone—Hyperhidrosis—Doxorubicin—liver cancer	0.000138	0.000847	CcSEcCtD
Amiodarone—Dyspnoea—Epirubicin—liver cancer	0.000137	0.000844	CcSEcCtD
Amiodarone—Anorexia—Doxorubicin—liver cancer	0.000136	0.000835	CcSEcCtD
Amiodarone—Dyspepsia—Epirubicin—liver cancer	0.000135	0.000833	CcSEcCtD
Amiodarone—Decreased appetite—Epirubicin—liver cancer	0.000134	0.000823	CcSEcCtD
Amiodarone—Hypotension—Doxorubicin—liver cancer	0.000133	0.000818	CcSEcCtD
Amiodarone—Gastrointestinal disorder—Epirubicin—liver cancer	0.000133	0.000817	CcSEcCtD
Amiodarone—Fatigue—Epirubicin—liver cancer	0.000133	0.000816	CcSEcCtD
Amiodarone—Pain—Epirubicin—liver cancer	0.000132	0.000809	CcSEcCtD
Amiodarone—Constipation—Epirubicin—liver cancer	0.000132	0.000809	CcSEcCtD
Amiodarone—Insomnia—Doxorubicin—liver cancer	0.000129	0.000792	CcSEcCtD
Amiodarone—Paraesthesia—Doxorubicin—liver cancer	0.000128	0.000786	CcSEcCtD
Amiodarone—Dyspnoea—Doxorubicin—liver cancer	0.000127	0.000781	CcSEcCtD
Amiodarone—Feeling abnormal—Epirubicin—liver cancer	0.000127	0.00078	CcSEcCtD
Amiodarone—Gastrointestinal pain—Epirubicin—liver cancer	0.000126	0.000774	CcSEcCtD
Amiodarone—Dyspepsia—Doxorubicin—liver cancer	0.000125	0.000771	CcSEcCtD
Amiodarone—Decreased appetite—Doxorubicin—liver cancer	0.000124	0.000761	CcSEcCtD
Amiodarone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000123	0.000756	CcSEcCtD
Amiodarone—Fatigue—Doxorubicin—liver cancer	0.000123	0.000755	CcSEcCtD
Amiodarone—Urticaria—Epirubicin—liver cancer	0.000122	0.000752	CcSEcCtD
Amiodarone—Constipation—Doxorubicin—liver cancer	0.000122	0.000749	CcSEcCtD
Amiodarone—Pain—Doxorubicin—liver cancer	0.000122	0.000749	CcSEcCtD
Amiodarone—Abdominal pain—Epirubicin—liver cancer	0.000122	0.000748	CcSEcCtD
Amiodarone—Body temperature increased—Epirubicin—liver cancer	0.000122	0.000748	CcSEcCtD
Amiodarone—Feeling abnormal—Doxorubicin—liver cancer	0.000117	0.000722	CcSEcCtD
Amiodarone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000116	0.000716	CcSEcCtD
Amiodarone—Hypersensitivity—Epirubicin—liver cancer	0.000113	0.000697	CcSEcCtD
Amiodarone—Urticaria—Doxorubicin—liver cancer	0.000113	0.000696	CcSEcCtD
Amiodarone—Abdominal pain—Doxorubicin—liver cancer	0.000113	0.000692	CcSEcCtD
Amiodarone—Body temperature increased—Doxorubicin—liver cancer	0.000113	0.000692	CcSEcCtD
Amiodarone—Asthenia—Epirubicin—liver cancer	0.00011	0.000679	CcSEcCtD
Amiodarone—Pruritus—Epirubicin—liver cancer	0.000109	0.00067	CcSEcCtD
Amiodarone—Diarrhoea—Epirubicin—liver cancer	0.000105	0.000648	CcSEcCtD
Amiodarone—Hypersensitivity—Doxorubicin—liver cancer	0.000105	0.000645	CcSEcCtD
Amiodarone—Asthenia—Doxorubicin—liver cancer	0.000102	0.000628	CcSEcCtD
Amiodarone—Dizziness—Epirubicin—liver cancer	0.000102	0.000626	CcSEcCtD
Amiodarone—Pruritus—Doxorubicin—liver cancer	0.000101	0.00062	CcSEcCtD
Amiodarone—Vomiting—Epirubicin—liver cancer	9.78e-05	0.000602	CcSEcCtD
Amiodarone—Diarrhoea—Doxorubicin—liver cancer	9.74e-05	0.000599	CcSEcCtD
Amiodarone—Rash—Epirubicin—liver cancer	9.7e-05	0.000597	CcSEcCtD
Amiodarone—Dermatitis—Epirubicin—liver cancer	9.69e-05	0.000596	CcSEcCtD
Amiodarone—Headache—Epirubicin—liver cancer	9.64e-05	0.000593	CcSEcCtD
Amiodarone—Dizziness—Doxorubicin—liver cancer	9.41e-05	0.000579	CcSEcCtD
Amiodarone—Nausea—Epirubicin—liver cancer	9.14e-05	0.000562	CcSEcCtD
Amiodarone—Vomiting—Doxorubicin—liver cancer	9.05e-05	0.000557	CcSEcCtD
Amiodarone—Rash—Doxorubicin—liver cancer	8.97e-05	0.000552	CcSEcCtD
Amiodarone—Dermatitis—Doxorubicin—liver cancer	8.97e-05	0.000552	CcSEcCtD
Amiodarone—Headache—Doxorubicin—liver cancer	8.92e-05	0.000549	CcSEcCtD
Amiodarone—Nausea—Doxorubicin—liver cancer	8.45e-05	0.00052	CcSEcCtD
Amiodarone—CYP2C9—Metabolism—HPGDS—liver cancer	9.32e-06	6.65e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	9.27e-06	6.61e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	9.26e-06	6.61e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—NR1H4—liver cancer	9.2e-06	6.56e-05	CbGpPWpGaD
Amiodarone—CACNA2D2—Metabolism—AKT1—liver cancer	9.17e-06	6.54e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—MTHFR—liver cancer	9.16e-06	6.53e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	9.14e-06	6.52e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CRABP1—liver cancer	9.11e-06	6.5e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PSMA4—liver cancer	9.11e-06	6.5e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PSMD10—liver cancer	9.11e-06	6.5e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTA3—liver cancer	9.04e-06	6.45e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	9.04e-06	6.45e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PPARA—liver cancer	8.98e-06	6.41e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PSMA4—liver cancer	8.89e-06	6.35e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PSMD10—liver cancer	8.89e-06	6.35e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—GSTP1—liver cancer	8.89e-06	6.34e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GOT2—liver cancer	8.86e-06	6.33e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—IL2—liver cancer	8.77e-06	6.26e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—HMOX1—liver cancer	8.77e-06	6.26e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—TERT—liver cancer	8.74e-06	6.24e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—CYCS—liver cancer	8.74e-06	6.23e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GOT2—liver cancer	8.65e-06	6.17e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—GOT1—liver cancer	8.57e-06	6.12e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—GGT1—liver cancer	8.57e-06	6.12e-05	CbGpPWpGaD
Amiodarone—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	8.48e-06	6.05e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.44e-06	6.02e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—GSTP1—liver cancer	8.4e-06	5.99e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PIK3CG—liver cancer	8.39e-06	5.99e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PSMA4—liver cancer	8.38e-06	5.98e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PSMD10—liver cancer	8.38e-06	5.98e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CYP2E1—liver cancer	8.33e-06	5.95e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.33e-06	5.95e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PSMA4—liver cancer	8.31e-06	5.93e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PSMD10—liver cancer	8.31e-06	5.93e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—HMOX1—liver cancer	8.28e-06	5.91e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTA4—liver cancer	8.27e-06	5.9e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	8.21e-06	5.86e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—GSTM1—liver cancer	8.17e-06	5.83e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GOT2—liver cancer	8.15e-06	5.82e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CYP2E1—liver cancer	8.13e-06	5.8e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PPARG—liver cancer	8.1e-06	5.78e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GOT2—liver cancer	8.08e-06	5.77e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.07e-06	5.76e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTA2—liver cancer	8.06e-06	5.75e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—KDR—liver cancer	7.99e-06	5.7e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—HPGDS—liver cancer	7.97e-06	5.68e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—MAPK14—liver cancer	7.94e-06	5.67e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.92e-06	5.65e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CYCS—liver cancer	7.8e-06	5.56e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—ESR1—liver cancer	7.79e-06	5.56e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTA1—liver cancer	7.78e-06	5.55e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—CYP1A1—liver cancer	7.75e-06	5.53e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—GSTM1—liver cancer	7.72e-06	5.51e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—GSTP1—liver cancer	7.7e-06	5.49e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—F2—liver cancer	7.69e-06	5.49e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PIK3CG—liver cancer	7.69e-06	5.49e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—NAT2—liver cancer	7.69e-06	5.49e-05	CbGpPWpGaD
Amiodarone—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	7.67e-06	5.47e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYP2E1—liver cancer	7.67e-06	5.47e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GGT1—liver cancer	7.65e-06	5.46e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GOT1—liver cancer	7.65e-06	5.46e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CYCS—liver cancer	7.61e-06	5.43e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYP2E1—liver cancer	7.6e-06	5.42e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—HMOX1—liver cancer	7.59e-06	5.42e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GOT1—liver cancer	7.47e-06	5.33e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GGT1—liver cancer	7.47e-06	5.33e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PPARG—liver cancer	7.42e-06	5.3e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PIK3CD—liver cancer	7.38e-06	5.26e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ALDOB—liver cancer	7.37e-06	5.26e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—APC—liver cancer	7.36e-06	5.25e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—PIK3CG—liver cancer	7.36e-06	5.25e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.36e-06	5.25e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—ALB—liver cancer	7.28e-06	5.2e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—MTHFR—liver cancer	7.22e-06	5.15e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	7.21e-06	5.15e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYCS—liver cancer	7.17e-06	5.12e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	7.12e-06	5.08e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYCS—liver cancer	7.11e-06	5.07e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PSMA4—liver cancer	7.1e-06	5.07e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PSMD10—liver cancer	7.1e-06	5.07e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PPARA—liver cancer	7.08e-06	5.05e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—GSTM1—liver cancer	7.08e-06	5.05e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GOT1—liver cancer	7.04e-06	5.02e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GGT1—liver cancer	7.04e-06	5.02e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CRABP1—liver cancer	7.03e-06	5.02e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GGT1—liver cancer	6.98e-06	4.98e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GOT1—liver cancer	6.98e-06	4.98e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—BRAF—liver cancer	6.92e-06	4.94e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GOT2—liver cancer	6.91e-06	4.93e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GSTP1—liver cancer	6.87e-06	4.9e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—MTHFR—liver cancer	6.82e-06	4.87e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—HMOX1—liver cancer	6.78e-06	4.84e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PIK3CD—liver cancer	6.76e-06	4.83e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GSTP1—liver cancer	6.71e-06	4.79e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—CYP1A1—liver cancer	6.71e-06	4.79e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PPARA—liver cancer	6.69e-06	4.78e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—ALB—liver cancer	6.68e-06	4.76e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—HMOX1—liver cancer	6.62e-06	4.72e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYP2E1—liver cancer	6.49e-06	4.63e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—PIK3CD—liver cancer	6.47e-06	4.62e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PIK3CB—liver cancer	6.43e-06	4.59e-05	CbGpPWpGaD
Amiodarone—ADRB1—GPCR downstream signaling—PIK3CA—liver cancer	6.41e-06	4.57e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—SERPINE1—liver cancer	6.4e-06	4.57e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—KRAS—liver cancer	6.34e-06	4.52e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GSTP1—liver cancer	6.32e-06	4.51e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—GSTM1—liver cancer	6.32e-06	4.51e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.29e-06	4.49e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GSTP1—liver cancer	6.27e-06	4.47e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—MTHFR—liver cancer	6.25e-06	4.46e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—HMOX1—liver cancer	6.23e-06	4.45e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—HMOX1—liver cancer	6.18e-06	4.41e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—GSTM1—liver cancer	6.17e-06	4.4e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—HPGDS—liver cancer	6.15e-06	4.39e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PPARA—liver cancer	6.14e-06	4.38e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYCS—liver cancer	6.08e-06	4.34e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PIK3CG—liver cancer	6.07e-06	4.33e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.01e-06	4.29e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—CYP1A1—liver cancer	5.99e-06	4.27e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GOT1—liver cancer	5.96e-06	4.25e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GGT1—liver cancer	5.96e-06	4.25e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PIK3CB—liver cancer	5.89e-06	4.21e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PPARG—liver cancer	5.86e-06	4.18e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—CYP1A1—liver cancer	5.84e-06	4.17e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—PIK3CA—liver cancer	5.82e-06	4.15e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—GSTM1—liver cancer	5.81e-06	4.15e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—RAF1—liver cancer	5.78e-06	4.12e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—GSTM1—liver cancer	5.76e-06	4.11e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PIK3CG—liver cancer	5.73e-06	4.09e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—PIK3CB—liver cancer	5.64e-06	4.03e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—MTOR—liver cancer	5.64e-06	4.03e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—MTHFR—liver cancer	5.58e-06	3.98e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PPARG—liver cancer	5.53e-06	3.95e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.51e-06	3.93e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—CYP1A1—liver cancer	5.51e-06	3.93e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PSMA4—liver cancer	5.48e-06	3.91e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PSMD10—liver cancer	5.48e-06	3.91e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PPARA—liver cancer	5.48e-06	3.91e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—CYP1A1—liver cancer	5.46e-06	3.9e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—MTHFR—liver cancer	5.45e-06	3.89e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—HRAS—liver cancer	5.39e-06	3.84e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GSTP1—liver cancer	5.36e-06	3.82e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PPARA—liver cancer	5.35e-06	3.81e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PIK3CD—liver cancer	5.33e-06	3.81e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GOT2—liver cancer	5.33e-06	3.8e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CDKN1B—liver cancer	5.29e-06	3.78e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—HMOX1—liver cancer	5.28e-06	3.77e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—ALB—liver cancer	5.26e-06	3.76e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PIK3CG—liver cancer	5.25e-06	3.75e-05	CbGpPWpGaD
Amiodarone—ADRB1—GPCR downstream signaling—AKT1—liver cancer	5.24e-06	3.74e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CASP3—liver cancer	5.19e-06	3.7e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—IL2—liver cancer	5.18e-06	3.7e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—IL6—liver cancer	5.16e-06	3.68e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—MTHFR—liver cancer	5.13e-06	3.66e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—MTHFR—liver cancer	5.09e-06	3.63e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PPARG—liver cancer	5.07e-06	3.62e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CCND1—liver cancer	5.05e-06	3.6e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—JUN—liver cancer	5.04e-06	3.6e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PIK3CD—liver cancer	5.04e-06	3.6e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PPARA—liver cancer	5.04e-06	3.59e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYP2E1—liver cancer	5.01e-06	3.58e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CTNNB1—liver cancer	5e-06	3.57e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PPARA—liver cancer	4.99e-06	3.56e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—ALB—liver cancer	4.97e-06	3.55e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—GSTM1—liver cancer	4.92e-06	3.51e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.92e-06	3.51e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—MMP9—liver cancer	4.9e-06	3.5e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—CDKN1A—liver cancer	4.89e-06	3.49e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—MAPK8—liver cancer	4.77e-06	3.4e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling by GPCR—AKT1—liver cancer	4.76e-06	3.39e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PIK3CG—liver cancer	4.69e-06	3.35e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYCS—liver cancer	4.69e-06	3.35e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—CYP1A1—liver cancer	4.67e-06	3.33e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PIK3CB—liver cancer	4.65e-06	3.32e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PIK3CD—liver cancer	4.62e-06	3.3e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GGT1—liver cancer	4.6e-06	3.28e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GOT1—liver cancer	4.6e-06	3.28e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PIK3CG—liver cancer	4.58e-06	3.27e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—ALB—liver cancer	4.56e-06	3.25e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PPARG—liver cancer	4.53e-06	3.23e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.49e-06	3.2e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PPARG—liver cancer	4.42e-06	3.15e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—VEGFA—liver cancer	4.4e-06	3.14e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PIK3CB—liver cancer	4.39e-06	3.13e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—STAT3—liver cancer	4.36e-06	3.11e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—MTHFR—liver cancer	4.35e-06	3.1e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PIK3CG—liver cancer	4.31e-06	3.08e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PIK3CG—liver cancer	4.28e-06	3.05e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PPARA—liver cancer	4.27e-06	3.04e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PPARG—liver cancer	4.16e-06	2.97e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTP1—liver cancer	4.13e-06	2.95e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PPARG—liver cancer	4.13e-06	2.95e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PIK3CD—liver cancer	4.12e-06	2.94e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—HMOX1—liver cancer	4.08e-06	2.91e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—ALB—liver cancer	4.07e-06	2.9e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—MYC—liver cancer	4.05e-06	2.89e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—TGFB1—liver cancer	4.04e-06	2.88e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PIK3CB—liver cancer	4.03e-06	2.87e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PIK3CD—liver cancer	4.02e-06	2.87e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—ALB—liver cancer	3.97e-06	2.83e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—PIK3CA—liver cancer	3.92e-06	2.8e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.83e-06	2.74e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—GSTM1—liver cancer	3.8e-06	2.71e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PIK3CD—liver cancer	3.79e-06	2.71e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PIK3CD—liver cancer	3.76e-06	2.68e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—KRAS—liver cancer	3.74e-06	2.67e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—ALB—liver cancer	3.74e-06	2.67e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—ALB—liver cancer	3.71e-06	2.65e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PIK3CG—liver cancer	3.65e-06	2.61e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—CYP1A1—liver cancer	3.6e-06	2.57e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PIK3CB—liver cancer	3.59e-06	2.56e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—PIK3CA—liver cancer	3.59e-06	2.56e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PPARG—liver cancer	3.53e-06	2.52e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PIK3CB—liver cancer	3.51e-06	2.5e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—PIK3CA—liver cancer	3.44e-06	2.45e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—MTHFR—liver cancer	3.36e-06	2.4e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—TP53—liver cancer	3.33e-06	2.37e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PIK3CB—liver cancer	3.31e-06	2.36e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PPARA—liver cancer	3.29e-06	2.35e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PIK3CB—liver cancer	3.28e-06	2.34e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PIK3CD—liver cancer	3.21e-06	2.29e-05	CbGpPWpGaD
Amiodarone—CYP3A7—Metabolism—AKT1—liver cancer	3.2e-06	2.29e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—HRAS—liver cancer	3.18e-06	2.27e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—ALB—liver cancer	3.17e-06	2.26e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—IL6—liver cancer	3.05e-06	2.17e-05	CbGpPWpGaD
Amiodarone—CYP2A6—Metabolism—AKT1—liver cancer	2.94e-06	2.09e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—PIK3CA—liver cancer	2.83e-06	2.02e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PIK3CG—liver cancer	2.82e-06	2.01e-05	CbGpPWpGaD
Amiodarone—ADRB1—Signaling Pathways—AKT1—liver cancer	2.81e-06	2e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PIK3CB—liver cancer	2.8e-06	2e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PPARG—liver cancer	2.72e-06	1.94e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—PIK3CA—liver cancer	2.68e-06	1.91e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PIK3CD—liver cancer	2.48e-06	1.77e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—PIK3CA—liver cancer	2.45e-06	1.75e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—ALB—liver cancer	2.45e-06	1.75e-05	CbGpPWpGaD
Amiodarone—CYP3A5—Metabolism—AKT1—liver cancer	2.31e-06	1.65e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—PIK3CA—liver cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Amiodarone—CYP1A1—Metabolism—AKT1—liver cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PIK3CB—liver cancer	2.16e-06	1.54e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—PIK3CA—liver cancer	2.14e-06	1.53e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—PIK3CA—liver cancer	2.02e-06	1.44e-05	CbGpPWpGaD
Amiodarone—CYP2C8—Metabolism—AKT1—liver cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—PIK3CA—liver cancer	2e-06	1.43e-05	CbGpPWpGaD
Amiodarone—CYP2C19—Metabolism—AKT1—liver cancer	1.79e-06	1.28e-05	CbGpPWpGaD
Amiodarone—ABCB1—Metabolism—AKT1—liver cancer	1.75e-06	1.25e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—PIK3CA—liver cancer	1.71e-06	1.22e-05	CbGpPWpGaD
Amiodarone—CYP2D6—Metabolism—AKT1—liver cancer	1.65e-06	1.17e-05	CbGpPWpGaD
Amiodarone—CYP2C9—Metabolism—AKT1—liver cancer	1.63e-06	1.16e-05	CbGpPWpGaD
Amiodarone—CYP1A2—Metabolism—AKT1—liver cancer	1.39e-06	9.95e-06	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—PIK3CA—liver cancer	1.32e-06	9.4e-06	CbGpPWpGaD
Amiodarone—CYP3A4—Metabolism—AKT1—liver cancer	1.08e-06	7.68e-06	CbGpPWpGaD
